The specificities and numbers of lymphocytes in animals are tightly controlled to avoid autoimmunity and to avoid accumulation of lymphocytes generated during previous infections. This control can be achieved through the death of autoreactive lymphocytes as consequence of selection events. Similarly, many lymphocytes that are generated in response to infections die when the infectious agent disappears. The lymphocyte repertoire is also influenced by the ability of lymphocytes to alter their antigen receptor. For example, the antigen receptor expressed by some autoreactive lymphocytes can be modified either by deletion of the genes encoding the offending receptor, or by silencing the action of the autoreactive receptor. At the peak of an immune response against a natural infection, a host can generate pathogen-specific T cell responses that comprise 20-50% of the hosts' total T cell pool. We have now identified a vaccination strategy that is able to generate a similar level of T cell expansion from a purely molecular based vaccine, a result not possible with previously developed vaccine strategies. These high levels of CD8+ T cell expansion can be achieved by the vaccination of a host with antigen in combination with agonists for both the Toll-Like Receptor (TLR) and CD40 pathways. We now have preliminary data demonstrating that both primary and memory CD8+ T cell responses elicited by combined TLR/CD40-agonist immunization occur independent of the presence of CD4+ T cells. This is in contrast to other immunization techniques in which memory CD8+ T cell responses are critically dependent upon the presence of CD4+ T cells. In the studies proposed here, the mechanism by which this immunization can generate CD4 independent CD8+ T cell responses will be investigated. These studies will yield information vital to the understanding of how potent cellular immunity can be generated even in the context of CD4 deficiency. Understanding these mechanisms is of critical importance, particularly for disease conditions where the existence of CD4+ T cell response is uncertain, such as in cancer, or is known to be absent and/or deficient, such as in HIV. These studies will lead to the development of more potent vaccines against these kinds of diseases whose treatment seems to require the quantity and quality of cellular immunity that only combined TLR/CD40-agonist immunization is capable of generating. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI068777-02
Application #
7269386
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Ferguson, Stacy E
Project Start
2006-08-01
Project End
2010-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
2
Fiscal Year
2007
Total Cost
$373,835
Indirect Cost
Name
University of Colorado Denver
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Pennock, Nathan D; Kedl, Justin D; Kedl, Ross M (2016) T Cell Vaccinology: Beyond the Reflection of Infectious Responses. Trends Immunol 37:170-180
Burchill, Matthew A; Tamburini, Beth A; Kedl, Ross M (2015) T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs. Eur J Immunol 45:3140-9
Desch, A Nicole; Gibbings, Sophie L; Clambey, Eric T et al. (2014) Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction. Nat Commun 5:4674
Sosinowski, Tomasz; White, Jason T; Cross, Eric W et al. (2013) CD8?+ dendritic cell trans presentation of IL-15 to naive CD8+ T cells produces antigen-inexperienced T cells in the periphery with memory phenotype and function. J Immunol 190:1936-47
Edwards, Lindsay E; Haluszczak, Catherine; Kedl, Ross M (2013) Phenotype and function of protective, CD4-independent CD8 T cell memory. Immunol Res 55:135-45
Sanchez, Phillip J; Kedl, Ross M (2012) An alternative signal 3: CD8? T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling. Vaccine 30:1154-61
Oh, Jason Z; Kurche, Jonathan S; Burchill, Matthew A et al. (2011) TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood 118:3028-38
Oh, Jason Z; Kedl, Ross M (2010) The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J Immunol 185:4602-8
McWilliams, Jennifer A; Sanchez, Phillip J; Haluszczak, Catherine et al. (2010) Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine 28:1468-76